Transaction details and immediate holdings
Aquestive Therapeutics (NASDAQ: AQST) Chief People Officer Peter E. Boyd sold 29,814 shares of the company's common stock on March 10, 2026, at prices ranging from $4.17 to $4.33 per share, resulting in proceeds of $124,413, according to a Form 4 filed with the Securities and Exchange Commission.
On the prior day, March 9, 2026, the same filing shows Boyd received 80,000 shares of common stock in the form of restricted stock. Those restricted shares are scheduled to vest in three equal annual installments. In addition to the restricted stock, Boyd was granted 42,500 Non-Qualified Stock Options with an exercise price of $4.29 and an expiration date of March 9, 2036. Those options also vest in three annual installments.
After accounting for the sale and the awards reported on the Form 4, Boyd directly owns 338,509 shares of Aquestive Therapeutics.
Context in the market
The companys shares are trading at $4.27, a price that sits near the upper end of Boyds reported sale price range. Over the past 12 months the stock has delivered a 62% return, a figure described in the filing as occurring despite recent volatility in the share price.
The sale itself was executed under an election by Aquestive Therapeutics within its equity incentive plans to cover tax withholding obligations tied to the restricted stock award. That procedural step mandated the disposition of a portion of the newly issued shares to satisfy tax liabilities.
Company financials and regulatory progress
In other company disclosures, Aquestive reported fourth-quarter 2025 results that showed a wider-than-expected loss. The firm recorded a net loss of $0.26 per share for the quarter, missing analyst expectations of a $0.13 loss per share. Revenue for Q4 2025 totaled $13 million, just under the anticipated $13.34 million.
On the regulatory front, Citizens has maintained a Market Outperform rating on Aquestive with a $10.00 price target, citing a clear path to re-submission of the Anaphylm NDA. The firm noted that an upcoming FDA meeting is scheduled to clarify the remaining steps, and Aquestive reiterated its plan to re-submit the NDA in the third quarter of 2026.
Valuation note and research access
Separate analysis from InvestingPro indicated that, at current levels, the stock appears overvalued relative to its Fair Value. The platform also referenced six additional ProTips available to subscribers and highlighted a Pro Research Report covering AQST among more than 1,400 U.S. equities.
What this means for stakeholders
These filings provide shareholders and market participants with a snapshot of insider equity activity, current ownership by a senior executive, short-term liquidity actions to meet tax obligations, and the company's recent operational results alongside a concrete regulatory timeline for a pending NDA re-submission. The combination of insider transactions, recent quarterly performance, and the regulatory calendar are pertinent inputs for investors monitoring Aquestive's near-term prospects.